6. Parkinson disease
2,123 clinical trials, 2,046 drugs (DrugBank: 324 drugs), 183 drug target genes, 198 drug target pathways
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02500108 (ClinicalTrials.gov) | May 2013 | 14/7/2015 | Domperidone and Risk of Sudden Cardiac Death | Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death | Parkinson's Disease | Drug: Domperidone | Canadian Network for Observational Drug Effect Studies, CNODES | Drug Safety and Effectiveness Network, Canada;Canadian Institutes of Health Research (CIHR) | Completed | 50 Years | N/A | Both | 214962 | N/A | Canada |
| 2 | NCT03022201 (ClinicalTrials.gov) | May 2013 | 23/11/2016 | Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease | Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial | Parkinson's Disease,Idiopathic | Drug: DA-9701;Drug: Domperidone;Drug: Placebo domperidone;Drug: Placebo DA-9701 | Seoul National University Hospital | NULL | Completed | 20 Years | 80 Years | All | 40 | Phase 4 | Korea, Republic of |
| 3 | JPRN-UMIN000007896 | 2012/05/01 | 07/05/2012 | Levodopa challenge test for Parkinson's disease and other parkinsonian syndromes | Parkinson's disease and other parkinsonian syndromes | The patients are given domperidone 30 mg/day for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day lactose powder is given to the patients and levodopa (250 mg)/carbidopa (25 mg) is given on the fifth day in a double-blind manner. On fourth and fifth day, motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug. The patients are given domperidone 30 mg/day (standard dose in Japan) for 3 days. When a patient is already on any anti-parkinson drugs, these drugs were withdrawn from the night before of the evaluation day. On the fourth day levodopa (250 mg)/carbidopa (25 mg) is given to the patients and lactose powder is given on the fifth day in a double-blind manner. Motor symptoms of the patients are examined using the Unified Parkinson's Disease Rating Scale motor scores by a clinician who is blind to the test drug. | Kansai Medical University | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 100 | Not selected | Japan | |
| 4 | NCT00305331 (ClinicalTrials.gov) | March 2006 | 20/3/2006 | Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease | Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease | Parkinson's Disease;Peripheral Edema | Drug: Domperidone (drug) | University Health Network, Toronto | NULL | Terminated | 30 Years | 90 Years | Both | 25 | Phase 2 | Canada |
| 5 | NCT00103597 (ClinicalTrials.gov) | January 2005 | 11/2/2005 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | NULL | Completed | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00006077 (ClinicalTrials.gov) | August 2000 | 4/8/2000 | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease | Parkinson's Disease | Drug: NS2330;Drug: Levodopa and Domperidone | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 50 | Phase 2 | United States |